Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...atment...
...ecommendation from 2022 Guideline Rapid...
...or patients with T1cN1-2 or T2-4N0 (stage II...
...ndidate...
...ant chemotherapy is the treatment of choice...
...ology, grade, stage and estrogen, progesterone, a...
...eoadjuvant systemic therapy should...
...vant systemic therapy may be offered to reduce...
...tients for whom a delay in surgery is preferable...
Measuring Response
...ring Response...
...s receiving neoadjuvant therapy should be...
...ssue-based biomarkers should not be used for...
..., defined as absence of invasive dis...
Recommended Regimens for Patients with TNBC
...commended Regimens for Patient...
...TNBC who have clinically node posi...
...cT1a or cT1bN0 TNBC should not routinely b...
...boplatin may be offered as part of a neo...
...ufficient evidence to recommend routinely a...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...ommended Neoadjuvant Treatment for Patie...
...ant chemotherapy can be used instea...
...pausal patients with HR+, HER2-negative disease...
...menopausal patients with HR+, HER2-ne...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...oadjuvant Treatment for Patients with HER...
...tients with node-positive or high-ris...
...T1a N0 and T1b N0, HER2+ disease should not be ro...